Eye-opening Ophthalmic Research

EyeCRO is composed of an internationally recognized team of research scientists focused on ophthalmic disease. The company, founded in 2005 with a contract to study the effects of one of the world’s largest pharmaceutical company’s drugs in an animal model, has only grown. EyeCRO started as a way to support the drug pipeline of a small pharmaceutical company, but quickly turned into a thriving business of its own, with a specialization in retinopathy, pharmacokinetics research, preclinical efficacy trials, and advanced laser technology. In short, no one knows the retina and advanced treatments and formulation better then the experts at Eyecro. With their associated backgrounds in formulation, study design, ocular surgery, veterinary, cell biology and molecular biology they bring a uniquely evolved mixture of expertise to the table for advanced therapies and compound testing and formulation. Their association with the University of Oklahoma Health Sciences Center allows EyeCRO to keep its costs down, while still providing the knowledge and competency to provide an exceptional product in a timely manner, leaving them the best solution for quick, budgetary services in the field of formulation of eye drops, depot forming injectables, microparticles, fluorescent micro and nanoparticles, and PLGA nanoparticles. As well as depot forming injectables, just to name a few. The team at Eyecro is constantly redefining what it means to be at the forefront of in vitro and in vivo preclinical efficacy testing and research, with reliable results and innovative techniques such as FDA approved polymers in vitreous depot delivery, and many other advanced technologies.